BACKGROUND: Outcomes of pulmonary physiology have a central place in asthma clinical research. OBJECTIVE: At the request of National Institutes of Health (NIH) institutes and other federal agencies, an expert group was convened to provide recommendations on the use of pulmonary function measures as asthma outcomes that should be assessed in a standardized fashion in future asthma clinical trials and studies to allow for cross-study comparisons. METHODS: Our subcommittee conducted a comprehensive search of PubMed to identify studies that focused on the validation of various airway response tests used in asthma clinical research. The subcommittee classified the instruments as core (to be required in future studies), supplemental (to be used according to study aims and in a standardized fashion), or emerging (requiring validation and standardization). This work was discussed at an NIH-organized workshop in March 2010 and finalized in September 2011. RESULTS: A list of pulmonary physiology outcomes that applies to both adults and children older than 6 years was created. These outcomes were then categorized into core, supplemental, and emerging. Spirometric outcomes (FEV(1), forced vital capacity, and FEV(1)/forced vital capacity ratio) are proposed as core outcomes for study population characterization, for observational studies, and for prospective clinical trials. Bronchodilator reversibility and prebronchodilator and postbronchodilator FEV(1) also are core outcomes for study population characterization and observational studies. CONCLUSIONS: The subcommittee considers pulmonary physiology outcomes of central importance in asthma and proposes spirometric outcomes as core outcomes for all future NIH-initiated asthma clinical research. Published by Mosby, Inc.
BACKGROUND: Outcomes of pulmonary physiology have a central place in asthma clinical research. OBJECTIVE: At the request of National Institutes of Health (NIH) institutes and other federal agencies, an expert group was convened to provide recommendations on the use of pulmonary function measures as asthma outcomes that should be assessed in a standardized fashion in future asthma clinical trials and studies to allow for cross-study comparisons. METHODS: Our subcommittee conducted a comprehensive search of PubMed to identify studies that focused on the validation of various airway response tests used in asthma clinical research. The subcommittee classified the instruments as core (to be required in future studies), supplemental (to be used according to study aims and in a standardized fashion), or emerging (requiring validation and standardization). This work was discussed at an NIH-organized workshop in March 2010 and finalized in September 2011. RESULTS: A list of pulmonary physiology outcomes that applies to both adults and children older than 6 years was created. These outcomes were then categorized into core, supplemental, and emerging. Spirometric outcomes (FEV(1), forced vital capacity, and FEV(1)/forced vital capacity ratio) are proposed as core outcomes for study population characterization, for observational studies, and for prospective clinical trials. Bronchodilator reversibility and prebronchodilator and postbronchodilator FEV(1) also are core outcomes for study population characterization and observational studies. CONCLUSIONS: The subcommittee considers pulmonary physiology outcomes of central importance in asthma and proposes spirometric outcomes as core outcomes for all future NIH-initiated asthma clinical research. Published by Mosby, Inc.
Authors: Kaharu Sumino; Elizabeth A Sugar; Charles G Irvin; David A Kaminsky; Dave Shade; Christine Y Wei; Janet T Holbrook; Robert A Wise; Mario Castro Journal: Ann Allergy Asthma Immunol Date: 2014-02-05 Impact factor: 6.347
Authors: Erin E Masterson; Lisa B Younglove; Adriana Perez; Elizabeth Torres; Jennifer E Krenz; Maria I Tchong French; Anne M Riederer; Paul D Sampson; Nervana Metwali; Esther Min; Karen L Jansen; Gino Aisenberg; Ryan S Babadi; Stephanie A Farquhar; Peter S Thorne; Catherine J Karr Journal: Contemp Clin Trials Date: 2020-07-25 Impact factor: 2.226
Authors: Kathryn L Colborn; Laura Helmkamp; Bruce G Bender; Bethany M Kwan; Lisa M Schilling; Marion R Sills Journal: J Am Board Fam Med Date: 2019 Jan-Feb Impact factor: 2.657
Authors: Sandra R Wilson; Michael J Mulligan; Estela Ayala; Alan Chausow; Qiwen Huang; Sarah B Knowles; Santosh Gummidipundi; Mario Castro; Robert A Wise Journal: J Allergy Clin Immunol Date: 2017-06-01 Impact factor: 10.793
Authors: Jacqueline A Pongracic; Rebecca Z Krouse; Denise C Babineau; Edward M Zoratti; Robyn T Cohen; Robert A Wood; Gurjit K Khurana Hershey; Carolyn M Kercsmar; Rebecca S Gruchalla; Meyer Kattan; Stephen J Teach; Christine C Johnson; Leonard B Bacharier; James E Gern; Steven M Sigelman; Peter J Gergen; Alkis Togias; Cynthia M Visness; William W Busse; Andrew H Liu Journal: J Allergy Clin Immunol Date: 2016-10 Impact factor: 10.793
Authors: Diana M Sobieraj; William L Baker; Elaine Nguyen; Erin R Weeda; Craig I Coleman; C Michael White; Stephen C Lazarus; Kathryn V Blake; Jason E Lang Journal: JAMA Date: 2018-04-10 Impact factor: 56.272
Authors: Stanley J Szefler; James F Chmiel; Anne M Fitzpatrick; George Giacoia; Thomas P Green; Daniel J Jackson; Heber C Nielsen; Wanda Phipatanakul; Hengameh H Raissy Journal: J Allergy Clin Immunol Date: 2013-11-28 Impact factor: 10.793